

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-102236-PIP01-25

Scope of the Application

Active Substance(s)

Enicepatide

Condition(s)

Treatment of type 2 diabetes mellitus

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

Subcutaneous use

Name / Corporate name of the PIP applicant

Roche Products Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Roche Products Limited submitted to the licensing authority on 22/05/2026 09:35 BST an application for a Paediatric Investigation Plan

The procedure started on 16/06/2026 13:57 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-102236-PIP01-25

Of 04/09/2026 13:33 BST

On the adopted decision for Enicepatide (MHRA-102236-PIP01-25) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for Enicepatide , Solution for injection , Subcutaneous use .

This decision is addressed to Roche Products Limited, Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, UNITED KINGDOM, AL7 1TW

ANNEX I

1. Waiver

1.1 Condition:

Treatment of type 2 diabetes mellitus The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 10 years of age Pharmaceutical form(s): Solution for injection Route(s) of administration: Subcutaneous use Reason for granting waiver: on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of type 2 diabetes mellitus

2.2 Indication(s) targeted by the PIP:

Treatment of type 2 diabetes mellitus

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 10 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	1	Study 1 Double-blind, randomised, placebo-controlled trial to evaluate efficacy, safety, and pharmacokinetics/ pharmacodynamics of enicepatide in paediatric patients from 10 years to less than 18 years of age with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin, or basal insulin, or both.
Extrapolation, Modeling & Simulation Studies	1	Study 2 Modelling and simulation analyses, to evaluate the use of enicepatide in paediatric patients from 10 years to less than 18 years of age with type 2 diabetes mellitus (T2DM).
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/03/2034
Deferral of one or more studies contained in the paediatric investigation plan:	Yes

